George R Uhl

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5092092/publications.pdf

Version: 2024-02-01

59 papers	4,520 citations	101384 36 h-index	149479 56 g-index
60 all docs	60 docs citations	60 times ranked	4396 citing authors

#	Article	IF	Citations
1	cDNA Cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Letters, 1994, 348, 75-79.	1.3	352
2	Human Î¼ opiate receptor. FEBS Letters, 1994, 338, 217-222.	1.3	255
3	Molecular Genetics of Successful Smoking Cessation. Archives of General Psychiatry, 2008, 65, 683.	13.8	227
4	Dopamine transporter immunoreactivity in rat brain. Journal of Comparative Neurology, 1995, 359, 340-349.	0.9	193
5	A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. Molecular Brain Research, 1992, 15, 161-166.	2.5	187
6	High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. American Journal of Medical Genetics Part A, 1997, 74, 439-442.	2.4	175
7	Phorbol Esters Increase Dopamine Transporter Phosphorylation and Decrease Transport V_{max}. Journal of Neurochemistry, 1997, 68, 225-232.	2.1	157
8	The Burden of Complex Genetics in Brain Disorders. Archives of General Psychiatry, 2004, 61, 223.	13.8	152
9	Addiction molecular genetics: 639,401 SNP whole genome association identifies many Ã¢Â€Âœcell adhesionÃ¢Â€Â• genes. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 918-925.	1.1	149
10	Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Annals of Neurology, 1994, 35, 494-498.	2.8	147
11	Molecular genetics of nicotine dependence and abstinence: whole genome association using 520,000 SNPs. BMC Genetics, 2007, 8, 10.	2.7	138
12	Hypothesis: The role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Annals of Neurology, 1998, 43, 555-560.	2.8	134
13	Genome-Wide Association for Methamphetamine Dependence. Archives of General Psychiatry, 2008, 65, 345.	13.8	130
14	Cholinergic axon terminals in the ventral tegmental area target a subpopulation of neurons expressing low levels of the dopamine transporter. Journal of Comparative Neurology, 1999, 410, 197-210.	0.9	125
15	Dopamine transporter mRNA expression is intense in rat midbrain neurons and modest outside midbrain. Molecular Brain Research, 1993, 18, 181-186.	2.5	121
16	The neurobiology of addiction. Annals of the New York Academy of Sciences, 2019, 1451, 5-28.	1.8	107
17	Dopamine transporter mutants selectively enhance MPP+ transport. Synapse, 1993, 15, 58-62.	0.6	104
18	Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature, 1984, 309, 350-352.	13.7	98

#	Article	IF	Citations
19	Molecular Mechanisms Underlying the Rewarding Effects of Cocaine. Annals of the New York Academy of Sciences, 2004, 1025, 47-56.	1.8	97
20	Dopamine transporter: Basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism. Movement Disorders, 2003, 18, S71-S80.	2.2	93
21	Pooled association genome scanning: Validation and use to identify addiction vulnerability loci in two samples. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11864-11869.	3.3	91
22	Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression. Molecular Brain Research, 1999, 73, 37-49.	2.5	89
23	NrCAM in Addiction Vulnerability: Positional Cloning, Drug-Regulation, Haplotype-Specific Expression, and Altered Drug Reward in Knockout Mice. Neuropsychopharmacology, 2006, 31, 572-584.	2.8	84
24	A human synaptic vesicle monoamine transporter cDNA predicts posttranslational modifications, reveals chromosome 10 gene localization and identifiesTaqI RFLPs. FEBS Letters, 1993, 318, 325-330.	1.3	74
25	Ultrastructural immunocytochemical localization of ? opioid receptors and Leu5-enkephalin in the patch compartment of the rat caudate-putamen nucleus. , 1996, 375, 659-674.		68
26	Dopamine transporter proline mutations influence dopamine uptake, cocaine analog recognition, and expression. FASEB Journal, 2000, 14, 715-728.	0.2	65
27	The VMAT2 gene in mice and humans: amphetamine responses, locomotion, cardiac arrhythmias, aging, and vulnerability to dopaminergic toxins. FASEB Journal, 2000, 14, 2459-2465.	0.2	65
28	Role for the C-Terminus in Agonist-Induced Î¼ Opioid Receptor Phosphorylation and Desensitizationâ€. Biochemistry, 2000, 39, 5492-5499.	1.2	65
29	Dopamine Transporter Cysteine Mutants: Second Extracellular Loop Cysteines Are Required for Transporter Expression. Journal of Neurochemistry, 1995, 64, 1416-1419.	2.1	61
30	Brain transcription factor gene expression, neurotransmitter levels, and novelty response behaviors: Alterations during rat amphetamine withdrawal and following chronic injection stress. Synapse, 1995, 19, 212-227.	0.6	56
31	PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes. Annals of the New York Academy of Sciences, 2019, 1451, 112-129.	1.8	55
32	Absence of G-protein activation by Î¼-opioid receptor agonists in the spinal cord of Î¼-opioid receptor knockout mice. British Journal of Pharmacology, 1999, 126, 451-456.	2.7	52
33	Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation. Sleep Medicine, 2017, 31, 71-77.	0.8	46
34	Common Human 5â€² Dopamine Transporter (SLC6A3) Haplotypes Yield Varying Expression Levels In Vivo. Cellular and Molecular Neurobiology, 2006, 26, 873-887.	1.7	45
35	Mouse Model for Protein Tyrosine Phosphatase D (PTPRD) Associations with Restless Leg Syndrome or Willis-Ekbom Disease and Addiction: Reduced Expression Alters Locomotion, Sleep Behaviors and Cocaine-Conditioned Place Preference. Molecular Medicine, 2015, 21, 717-725.	1.9	45
36	Acetylcholinesterase-immunoreactive axonal network in monkey visual cortex. Journal of Comparative Neurology, 1984, 226, 246-254.	0.9	44

#	Article	IF	Citations
37	Species Differences in Dopamine Transporters: Postmortem Changes and Glycosylation Differences. Journal of Neurochemistry, 1993, 61, 496-500.	2.1	43
38	â€œReplicatedâ€•genome wide association for dependence on illegal substances: Genomic regions identified by overlapping clusters of nominally positive SNPs. , 2011, 156, 125-138.		37
39	Human cell adhesion molecules: annotated functional subtypes and overrepresentation of addictionâ€ssociated genes. Annals of the New York Academy of Sciences, 2015, 1349, 83-95.	1.8	33
40	Cocaine reward is reduced by decreased expression of receptor-type protein tyrosine phosphatase D (PTPRD) and by a novel PTPRD antagonist. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 11597-11602.	3.3	33
41	Opioid peptide gene expression in rat trigeminal nucleus caudalis neurons: Normal distribution and effects of trigeminal deafferentation. Journal of Comparative Neurology, 1988, 274, 142-150.	0.9	29
42	Localization and regulation of vasopressin mRNA in human neurons. Synapse, 1989, 3, 246-254.	0.6	27
43	Murine serotonin transporter: sequence and localization to Chromosome 11. Mammalian Genome, 1993, 4, 283-284.	1.0	26
44	Cadherin 13: Human cis-Regulation and Selectively Altered Addiction Phenotypes and Cerebral Cortical Dopamine in Knockout Mice. Molecular Medicine, 2016, 22, 537-547.	1.9	26
45	Proenkephalin transgenic mice: A short promoter confers high testis expression and reduced fertility. Molecular Reproduction and Development, 1994, 38, 275-284.	1.0	22
46	Preproenkephalin upregulation in nucleus caudalis: High and low intensity afferent stimulation differentially modulate early and late responses. Journal of Comparative Neurology, 1990, 302, 1002-1018.	0.9	18
47	Cell Adhesion Molecules: Druggable Targets for Modulating the Connectome and Brain Disorders?. Neuropsychopharmacology, 2014, 39, 235-235.	2.8	13
48	Sex differences in the effects of adolescent social deprivation on alcohol consumption in Î¼-opioid receptor knockout mice. Psychopharmacology, 2015, 232, 1471-1482.	1.5	11
49	Exclusion of close linkage between the synaptic vesicular monoamine transporter locus and schizophrenia spectrum disorders. American Journal of Medical Genetics Part A, 1995, 60, 563-565.	2.4	10
50	Evaluating the genetic susceptibility to peer reported bullying behaviors. Psychiatry Research, 2018, 263, 193-198.	1.7	8
51	Improved visual discrimination learning in mice with partial 5-HT2B gene deletion. Neuroscience Letters, 2020, 738, 135378.	1.0	7
52	Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities. Annals of Clinical and Translational Neurology, 2019, 6, 406-415.	1.7	6
53			

#	Article	IF	Citations
55	In vivo evaluation of effects of histamine H3 receptor antagonists on methamphetamine-induced hyperlocomotion in mice. Brain Research, 2020, 1740, 146873.	1.1	5
56	Elucidating Neurotensin Receptor cDNAs and Their Distribution. Annals of the New York Academy of Sciences, 1992, 668, 101-108.	1.8	3
57	Metoprine, a histamine N-methyltransferase inhibitor, attenuates methamphetamine-induced hyperlocomotion via activation of histaminergic neurotransmission in mice. Pharmacology Biochemistry and Behavior, 2021, 209, 173257.	1.3	3
58	Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development. Biochemical Pharmacology, 2022, 195, 114868.	2.0	2
59	Substrate-selective positive allosteric modulation of PTPRDâ€™s phosphatase by flavonols. Biochemical Pharmacology, 2022, 202, 115109.	2.0	1